Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 20.48
NVIV's Cash-to-Debt is ranked lower than
52% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NVIV: 20.48 )
Ranked among companies with meaningful Cash-to-Debt only.
NVIV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 20.48 Max: No Debt
Current: 20.48
Debt-to-Equity 0.06
NVIV's Debt-to-Equity is ranked higher than
82% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NVIV: 0.06 )
Ranked among companies with meaningful Debt-to-Equity only.
NVIV' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.01  Med: 0.04 Max: 0.33
Current: 0.06
-1.01
0.33
Piotroski F-Score: 3
Altman Z-Score: -6.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -85.57
NVIV's ROE % is ranked lower than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NVIV: -85.57 )
Ranked among companies with meaningful ROE % only.
NVIV' s ROE % Range Over the Past 10 Years
Min: -775.86  Med: -325.82 Max: -85.57
Current: -85.57
-775.86
-85.57
ROA % -71.52
NVIV's ROA % is ranked lower than
72% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NVIV: -71.52 )
Ranked among companies with meaningful ROA % only.
NVIV' s ROA % Range Over the Past 10 Years
Min: -1218.1  Med: -233.77 Max: 42.86
Current: -71.52
-1218.1
42.86
ROC (Joel Greenblatt) % -4707.10
NVIV's ROC (Joel Greenblatt) % is ranked lower than
78% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NVIV: -4707.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVIV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13352.31  Med: -2134.11 Max: 334.46
Current: -4707.1
-13352.31
334.46
3-Year EBITDA Growth Rate -29.00
NVIV's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NVIV: -29.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVIV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.2  Med: -31.15 Max: 489.6
Current: -29
-62.2
489.6
3-Year EPS without NRI Growth Rate -28.70
NVIV's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NVIV: -28.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVIV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.5 Max: 274.4
Current: -28.7
0
274.4
GuruFocus has detected 1 Warning Sign with InVivo Therapeutics Holdings Corp $NVIV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVIV's 30-Y Financials

Financials (Next Earnings Date: 2017-11-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NVIV Guru Trades in

NVIV Guru Trades in

Q1 2016

NVIV Guru Trades in Q1 2016

Jim Simons 31,700 sh (New)
» More
Q2 2016

NVIV Guru Trades in Q2 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2836
Compare:NAS:NTRP, NAS:APVO, OTCPK:CDXI, NAS:OHRP, NAS:HSGX, NAS:PTI, OTCPK:DYAI, NAS:AZRX, NAS:ONS, NAS:OPNT, NAS:ZSAN, NAS:GNMX, NAS:SNSS, NAS:OVAS, NAS:CATB, OTCPK:CRYO, NAS:MBRX, NAS:ALT, AMEX:ATNM, NAS:CSBR » details
Traded in other countries:04IA.Germany,
Headquarter Location:USA
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 2.29
NVIV's PB Ratio is ranked higher than
53% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NVIV: 2.29 )
Ranked among companies with meaningful PB Ratio only.
NVIV' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.07
Current: 2.29
0
5.07
EV-to-EBIT -1.05
NVIV's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NVIV: -1.05 )
Ranked among companies with meaningful EV-to-EBIT only.
NVIV' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.36  Med: 0 Max: 0
Current: -1.05
-4.36
0
EV-to-EBITDA -1.07
NVIV's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NVIV: -1.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVIV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.46  Med: 0 Max: 0
Current: -1.07
-4.46
0
Current Ratio 5.89
NVIV's Current Ratio is ranked higher than
67% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NVIV: 5.89 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 2.5 Max: 14.81
Current: 5.89
0.14
14.81
Quick Ratio 5.89
NVIV's Quick Ratio is ranked higher than
68% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NVIV: 5.89 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 2.5 Max: 14.81
Current: 5.89
0.14
14.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.60
NVIV's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NVIV: -17.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVIV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -121  Med: -50.45 Max: -17.6
Current: -17.6
-121
-17.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.50
NVIV's Price-to-Net-Cash is ranked higher than
72% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. NVIV: 2.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NVIV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.39  Med: 10.77 Max: 48
Current: 2.5
2.39
48
Price-to-Net-Current-Asset-Value 2.37
NVIV's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. NVIV: 2.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVIV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.26  Med: 10.29 Max: 34.94
Current: 2.37
2.26
34.94
Price-to-Tangible-Book 2.29
NVIV's Price-to-Tangible-Book is ranked higher than
61% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NVIV: 2.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVIV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 9.34 Max: 29.63
Current: 2.29
2.19
29.63
Earnings Yield (Greenblatt) % -95.22
NVIV's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NVIV: -95.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVIV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -753.2  Med: 0 Max: 0
Current: -95.22
-753.2
0

More Statistics

EPS (TTM) $ -0.76
Beta3.20
Short Percentage of Float7.91%
52-Week Range $1.10 - 6.97
Shares Outstanding (Mil)34.21

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27 151
EPS ($) -1.16 -0.89 2.05
EPS without NRI ($) -1.16 -0.89 2.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of InVivo Therapeutics Jul 31 2017 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}